Abstract | BACKGROUND: METHODS: RESULTS: Randomized trials of type I antiarrhythmic agents used as secondary prevention after myocardial infarction show an overall 21% increase in mortality rate. Randomized trials of amiodarone suggest a 13% to 19% decrease in mortality rate, and sotalol has been effective in several small trials. Trials of pure type III agents, however, have shown no mortality benefit. An overview of implantable defibrillator trials shows a 24% reduction in mortality rate (CI 15%-33%) compared with alternative therapy, most often amiodarone. CONCLUSION:
|
Authors | Paul A Heidenreich, Brian Keeffe, Kathryn M McDonald, Mark A Hlatky |
Journal | American heart journal
(Am Heart J)
Vol. 144
Issue 3
Pg. 422-30
(Sep 2002)
ISSN: 1097-6744 [Electronic] United States |
PMID | 12228778
(Publication Type: Comparative Study, Journal Article, Meta-Analysis, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Anti-Arrhythmia Agents
- Sotalol
- Amiodarone
|
Topics |
- Aged
- Amiodarone
(therapeutic use)
- Anti-Arrhythmia Agents
(therapeutic use)
- Death, Sudden, Cardiac
(prevention & control)
- Defibrillators, Implantable
(statistics & numerical data)
- Female
- Humans
- Male
- Middle Aged
- Myocardial Infarction
(drug therapy, mortality, therapy)
- Randomized Controlled Trials as Topic
- Sotalol
(therapeutic use)
|